Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis. [electronic resource]
Producer: 20180326Description: 1288-1296 p. digitalISSN:- 1365-2133
- Adalimumab -- therapeutic use
- Biological Products -- therapeutic use
- Dermatologic Agents -- therapeutic use
- Etanercept -- therapeutic use
- Female
- Genetic Markers
- Humans
- Interleukin-12 Subunit p40 -- genetics
- Male
- Middle Aged
- Polymorphism, Single Nucleotide -- genetics
- Psoriasis -- drug therapy
- Signaling Lymphocytic Activation Molecule Family -- genetics
- Treatment Outcome
- Tumor Necrosis Factor alpha-Induced Protein 3 -- genetics
- Ustekinumab -- therapeutic use
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.